相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
Quang A. Le et al.
ANNALS OF PHARMACOTHERAPY (2019)
Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial
P. D. Miller et al.
BONE (2019)
Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption
N. Doyle et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial
J. P. Bilezikian et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
Jean-Yves Reginster et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Long-term treatment strategies for postmenopausal osteoporosis
Felicia Cosman
CURRENT OPINION IN RHEUMATOLOGY (2018)
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist
Eric G. Boyce et al.
ANNALS OF PHARMACOTHERAPY (2018)
Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption
Aurore Varela et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial
Felicia Cosman et al.
MAYO CLINIC PROCEEDINGS (2017)
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34)
Jacquelin Jolette et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2017)
Osteoporosis treatment: recent developments and ongoing challenges
Sundeep Khosla et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial
Carolina A. Moreira et al.
BONE (2017)
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling
Gary Hattersley et al.
ENDOCRINOLOGY (2016)
Treatment needs and current options for postmenopausal osteoporosis
Luigi Gennari et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Impact of the US Food and Drug Administration's Safety-Related Announcements on the use of Bisphosphonates After Hip Fracture
Seoyoung C. Kim et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Postmenopausal Osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Future directions for new medical entities in osteoporosis
Serge Ferrari
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Trends in Fracture Incidence: A Population-Based Study Over 20 Years
Shreyasee Amin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches
Felicia Cosman
CURRENT OSTEOPOROSIS REPORTS (2014)
Effects of Different Dosages of Parathyroid Hormone-Related Protein 1-34 on the Bone Metabolism of the Ovariectomized Rat Model of Osteoporosis
Jin Xu et al.
CALCIFIED TISSUE INTERNATIONAL (2013)
Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013
J. Compston et al.
MATURITAS (2013)
The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years
Elizabeth B. Andrews et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Benefits and Risks of Bisphosphonate Therapy for Osteoporosis
Sundeep Khosla et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
Alexandra Papaioannou et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
G protein and its signaling pathway in bone development and disease
Mengrui Wu et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2010)
Parathyroid hormone signaling in bone and kidney
Minnkyong Lee et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2009)
Sustained cyclic AMP production by parathyroid hormone receptor endocytosis
Sebastien Ferrandon et al.
NATURE CHEMICAL BIOLOGY (2009)
Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease
Ann E. Kearns et al.
ENDOCRINE REVIEWS (2008)
Altered selectivity of parathyroid hormone (PTH) and PTH-Related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor
Thomas Dean et al.
MOLECULAR ENDOCRINOLOGY (2008)
Mechanisms of anabolic therapies for osteoporosis
Ernesto Canalis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Selective estrogen receptor modulators for postmenopausal osteoporosis - Current state of development
Luigi Gennari et al.
DRUGS & AGING (2007)
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
G-protein signaling: back to the future
CR McCudden et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
New anabolic therapies in osteoporosis
MR Rubin et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2003)
Seven-transmembrane receptors
KL Pierce et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Epidemiology and outcomes of osteoporotic fractures
SR Cummings et al.
LANCET (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893
AF Stewart et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
分享论文
